Lupin Ltd
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
- Market Cap ₹ 73,624 Cr.
- Current Price ₹ 1,616
- High / Low ₹ 1,704 / 695
- Stock P/E 41.1
- Book Value ₹ 291
- Dividend Yield 0.25 %
- ROCE 5.73 %
- ROE 3.33 %
- Face Value ₹ 2.00
Pros
- Company has been maintaining a healthy dividend payout of 18.2%
Cons
- Stock is trading at 5.56 times its book value
- The company has delivered a poor sales growth of 1.05% over past five years.
- Company has a low return on equity of 0.07% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
7,083 | 9,641 | 11,286 | 12,770 | 14,256 | 17,367 | 15,797 | 14,665 | 15,375 | 15,163 | 16,405 | 16,642 | 19,480 | |
5,620 | 7,356 | 8,271 | 9,146 | 10,564 | 12,865 | 12,649 | 12,104 | 13,020 | 12,596 | 16,187 | 14,921 | 16,090 | |
Operating Profit | 1,463 | 2,284 | 3,015 | 3,624 | 3,691 | 4,502 | 3,148 | 2,561 | 2,355 | 2,567 | 219 | 1,721 | 3,390 |
OPM % | 21% | 24% | 27% | 28% | 26% | 26% | 20% | 17% | 15% | 17% | 1% | 10% | 17% |
-3 | 13 | 105 | 235 | 184 | 106 | -1,310 | 91 | -134 | 138 | 210 | 151 | 130 | |
Interest | 35 | 41 | 27 | 10 | 59 | 153 | 204 | 302 | 363 | 141 | 143 | 274 | 333 |
Depreciation | 228 | 332 | 261 | 435 | 487 | 912 | 1,086 | 846 | 970 | 887 | 1,659 | 881 | 1,004 |
Profit before tax | 1,196 | 1,925 | 2,832 | 3,415 | 3,329 | 3,543 | 547 | 1,503 | 887 | 1,676 | -1,372 | 716 | 2,183 |
Tax % | 26% | 30% | 34% | 28% | 32% | 28% | 53% | 59% | 130% | 27% | -10% | 38% | |
888 | 1,340 | 1,870 | 2,444 | 2,270 | 2,565 | 258 | 615 | -270 | 1,228 | -1,528 | 430 | 1,810 | |
EPS in Rs | 19.43 | 29.36 | 40.96 | 53.47 | 50.17 | 56.63 | 5.56 | 13.40 | -5.95 | 26.81 | -33.62 | 9.45 | 39.36 |
Dividend Payout % | 18% | 14% | 15% | 14% | 15% | 13% | 90% | 37% | -101% | 24% | -12% | 42% |
Compounded Sales Growth | |
---|---|
10 Years: | 6% |
5 Years: | 1% |
3 Years: | 3% |
TTM: | 21% |
Compounded Profit Growth | |
---|---|
10 Years: | -11% |
5 Years: | 8% |
3 Years: | 42% |
TTM: | 668% |
Stock Price CAGR | |
---|---|
10 Years: | 5% |
5 Years: | 13% |
3 Years: | 15% |
1 Year: | 133% |
Return on Equity | |
---|---|
10 Years: | 8% |
5 Years: | 0% |
3 Years: | 0% |
Last Year: | 3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 89 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 91 | 91 | 91 | 91 | 91 |
Reserves | 3,924 | 5,115 | 6,842 | 8,784 | 11,073 | 13,407 | 13,487 | 13,652 | 12,446 | 13,712 | 12,062 | 12,374 | 13,148 |
1,639 | 1,164 | 654 | 537 | 7,178 | 7,966 | 7,143 | 8,496 | 6,305 | 5,129 | 4,158 | 4,542 | 3,785 | |
2,283 | 2,475 | 2,550 | 3,642 | 3,957 | 4,749 | 5,300 | 5,423 | 5,968 | 4,498 | 5,340 | 5,794 | 6,420 | |
Total Liabilities | 7,935 | 8,843 | 10,135 | 13,054 | 22,298 | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,444 |
2,750 | 3,000 | 3,356 | 4,368 | 8,717 | 11,033 | 10,362 | 11,087 | 7,938 | 7,881 | 7,382 | 8,355 | 9,246 | |
CWIP | 444 | 311 | 304 | 576 | 2,702 | 2,133 | 2,598 | 1,640 | 940 | 1,066 | 1,146 | 1,238 | 676 |
Investments | 3 | 2 | 178 | 1,658 | 16 | 2,136 | 262 | 2,295 | 2,374 | 2,455 | 900 | 517 | 164 |
4,739 | 5,530 | 6,297 | 6,451 | 10,862 | 10,910 | 12,798 | 12,639 | 13,557 | 12,028 | 12,224 | 12,690 | 13,359 | |
Total Assets | 7,935 | 8,843 | 10,135 | 13,054 | 22,298 | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,444 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
560 | 1,251 | 2,004 | 2,733 | -382 | 4,114 | 1,751 | 1,666 | 1,469 | 1,822 | 367 | 1,897 | |
-720 | -522 | -851 | -1,034 | -6,769 | -2,527 | 470 | -3,282 | 1,107 | -1,240 | 1,292 | -1,287 | |
109 | -663 | -857 | -197 | 5,836 | 433 | -1,492 | 744 | -891 | -1,885 | -1,572 | -337 | |
Net Cash Flow | -51 | 66 | 296 | 1,502 | -1,315 | 2,019 | 729 | -872 | 1,685 | -1,303 | 87 | 273 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 92 | 83 | 80 | 76 | 116 | 91 | 120 | 128 | 129 | 108 | 95 | 98 |
Inventory Days | 243 | 200 | 204 | 220 | 276 | 266 | 253 | 283 | 232 | 279 | 261 | 242 |
Days Payable | 193 | 159 | 152 | 172 | 168 | 189 | 178 | 184 | 162 | 137 | 129 | 136 |
Cash Conversion Cycle | 141 | 125 | 131 | 124 | 225 | 167 | 195 | 227 | 199 | 249 | 227 | 204 |
Working Capital Days | 96 | 92 | 94 | 67 | 147 | 112 | 137 | 154 | 92 | 151 | 135 | 127 |
ROCE % | 24% | 33% | 41% | 40% | 24% | 19% | 10% | 10% | 9% | 9% | -7% | 6% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 1d
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
2d - Lupin receives EIR from U.S. FDA for its Aurangabad Manufacturing Plant.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
23 Apr - Earnings Call for Q4 FY24 is scheduled on Tuesday, May 7, 2024 at 16:00 hrs (IST).
- Board Meeting Intimation for Considering And Taking On Record Audited Financial Results Of The Company For The Quarter And Year-Ended March 31, 2024 And Recommending Dividend, If Any. 22 Apr
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
20 Apr - Lupin Launches Mirabegron Extended-Release Tablets in the United States.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Jan 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Jan 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
May 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Jan 2021TranscriptNotesPPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptPPT
-
Jun 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Jan 2020TranscriptNotesPPT
-
Nov 2019TranscriptPPT
-
Nov 2019Transcript PPT
-
Aug 2019TranscriptNotesPPT
-
May 2019TranscriptNotesPPT
-
Feb 2019Transcript PPT
-
Jan 2019TranscriptNotesPPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
Jun 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Jan 2018TranscriptNotesPPT
-
Nov 2017Transcript PPT
-
Sep 2017TranscriptNotesPPT
-
Aug 2017TranscriptNotesPPT
-
May 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
-
Jan 2017TranscriptNotesPPT
-
Nov 2016TranscriptNotesPPT
-
Jun 2016TranscriptPPT
Products
Co. is engaged in developing and marketing generic formulations, biotechnology products, and APIs globally. Co. has a significant presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, and Central Nervous system, among other segments, and is a global leader in e Anti-TB and Cephalosporins segments. [1]